TITLE:
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

CONDITION:
Major Depressive Disorder

INTERVENTION:
DVS-233 SR

SUMMARY:

      Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR
      versus subjects receiving placebo.

      Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global
      evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric
      Rating Scale for Depression, 17-item [HAM-D<sub>17</sub>] < 7) versus those subjects
      receiving placebo.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Subjects must have a primary diagnosis of major depressive disorder (MDD)

          -  Depressive symptoms for at least 30 days prior to the screening visit

          -  Minimum screening and study day -1 (baseline) scores of 20 on the Hamilton
             Psychiatric Rating Scale for Depression (HAM D<sub>17</sub>)

        Exclusion Criteria:

          -  Treatment with DVS-233 SR at any time in the past

          -  Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within
             90 days of study day 1

          -  Known hypersensitivity to venlafaxine (IR or ER)
      
